
Procurement teams sourcing refrigerated benchtop centrifuges for clinical trial programs now have an option purpose-built for that application: the LX-60T100R, jointly developed by Haier Biomedical and Resonant Clinical Solutions. Using R290, a natural hydrocarbon refrigerant with a Global Warming Potential (GWP) of approximately 3, Resonant and Haier position it as a compliance-ready replacement for legacy F-gas systems that register above 1,400 GWP.
Passed in 2024, EU F-Gas Regulation (2024/573) includes laboratory centrifuges in a derogation permitting continued use of F-gas refrigerants with GWP of 150 or higher through December 31, 2028. After that date, organizations procuring new equipment in the EU will need compliant alternatives. Buying a non-compliant instrument now shortens its useful capital life before mandatory replacement, a material planning risk for any organization running multi-year clinical programs.
Eight specification points cover performance, compliance, footprint, and sourcing constraints relevant to the buying decision.
Buyer's note: The 110 V AC model for most North American facilities does not ship until Q1 2027; organizations targeting 2026 deployment should plan accordingly. The exclusivity agreement with Resonant covers the clinical trials market globally, excluding China. Buyers outside that segment or in China should contact Haier Biomedical directly.
Fit depends on three variables: F-gas compliance timeline, speed requirements, and distribution channel access.
The instrument's value concentrates in specific workflow contexts; matching those to your lab type before procurement avoids a feature mismatch.
For sponsors and CROs managing clinical sample workflows, this instrument's combined F-gas compliance and rental availability address constraints few other platforms resolve simultaneously. Rental is worth evaluating for programs with defined enrollment windows, since most comparable instruments require capital purchase. European sponsors should confirm with their regulatory affairs team whether R290 handling certification applies at their specific clinical sites.
Labs with environmental, social, and governance reporting requirements will find R290's GWP of approximately 3 is independently verifiable against published refrigerant data, making it a defensible sustainability claim rather than marketing language. Without clinical trial traceability mandates, however, a simpler R290-equipped platform may deliver comparable environmental benefit at lower cost. Buyers should weigh whether the full program-management feature set justifies the price difference before procurement.
As the 2028 deadline approaches, more manufacturers are releasing R290-compliant centrifuges, narrowing the LX-60T100R's first-mover compliance advantage. CDMOs and diagnostic labs whose procurement channels do not run through Resonant, or who need the 110 V model before Q1 2027, face real sourcing constraints. Evaluating alternative R290 platforms in parallel is advisable for organizations in this segment.
Regulated-workflow notice: The press release does not specify Installation, Operational, Performance Qualification (IQ/OQ/PQ) documentation packages, In Vitro Diagnostic (IVD) compliance status, or 21 CFR Part 11 readiness for the US market. Buyers procuring for GMP or regulated clinical environments should request qualification documentation from Resonant Clinical Solutions before purchase. EU buyers must also confirm that EU IVD Regulation (2017/746) classification requirements are met, separate from F-gas compliance obligations.
Christophe Berthoux, CEO at Resonant Clinical Solutions, said: “We are laser-focused on providing world-class, customer-centric solutions that support the full lifecycle of complex clinical trial programs. Our collaboration with Haier Biomedical on this reimagined natural-refrigerant centrifuge has been pivotal in delivering innovative, globally supported technology that meets F-gas regulatory requirements and market demand, years ahead of mandated deadlines.” Procurement teams should use that framing as a prompt to ask Resonant directly about regulatory documentation and F-gas transition support, not just instrument performance.
“Our ability to turn a concept into an innovative product in such a short period really shows our commitment to supporting our customers,” said Gang Liu, Co-CEO at Haier Biomedical. Listed on the Shanghai Stock Exchange STAR Market and active across 160-plus countries, Haier Biomedical maintains established UK service and distribution infrastructure, a practical consideration for European clinical trial sites assessing post-purchase support coverage.
The LX-60T100R is among the first refrigerated benchtop centrifuges purpose-built for clinical trials to use R290 natural refrigerant, giving procurement teams a verified compliance path ahead of the EU F-gas deadline for laboratory centrifuges. Its rental availability through Resonant Clinical Solutions and narrow clinical trial focus make it best suited to sponsors and CROs rather than general-purpose research labs. Browse current inventory in the LabX Centrifuges category, and contact Resonant Clinical Solutions for pricing, rental terms, and qualification documentation.
This article draws on a Resonant Clinical Solutions press release and was created with the assistance of Generative AI and has undergone editorial review before publishing. LabX's editorial policy can be found here.